Shukla H S, Hughes L E, Davis P W, Whitehead R H, Leach K G
Am J Surg. 1977 Mar;133(3):346-50. doi: 10.1016/0002-9610(77)90543-8.
The distribution of 5-fluorouracil (5-FU) to various potential metastatic sites has been investigated in stomach and colorectal cancer patients, using intraluminal, intravenous, and intramural routes of administration at the time of surgery. The best overall concentrations of 5-FU in systemic blood, portal blood, liver, draining lymph nodes, tumor, and locally in the bowel wall was obtained after intramural injection. The intraluminal route of administration resulted in poor overall distribution of 5-FU. Intravenous administration tended to give levels between those obtained from intramural and intraluminal routes. There was no complication of 5-FU therapy. On the basis of this study we conclude that the intramural route is the most satisfactory for adjuvant administration of 5-FU with surgery. This might be expected to give better results than those obtained in clinical studies using intraluminal and intravenous routes. A controlled trial of 5-FU using the intramural route is indicated in gastric and colorectal cancer to demonstrate whether or not clinical benefit can be obtained.
在胃癌和结直肠癌患者中,研究了手术时通过腔内、静脉内和壁内途径给药5-氟尿嘧啶(5-FU)后其在各种潜在转移部位的分布情况。壁内注射后,全身血液、门静脉血、肝脏、引流淋巴结、肿瘤以及肠壁局部的5-FU总体浓度最佳。腔内给药途径导致5-FU总体分布不佳。静脉内给药的水平往往介于壁内和腔内给药途径所获得的水平之间。5-FU治疗未出现并发症。基于这项研究,我们得出结论,壁内途径是5-FU与手术辅助给药最令人满意的途径。这可能会比使用腔内和静脉内途径的临床研究取得更好的结果。在胃癌和结直肠癌中,有必要进行一项使用壁内途径的5-FU对照试验,以证明是否能获得临床益处。